About this FactMed analysis covering adverse side effect reports of EFALIZUMAB patients who developed ADRENALITIS.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 1 individuals taking EFALIZUMAB reported ADRENALITIS to the FDA. A total of 268 EFALIZUMAB drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between EFALIZUMAB and ADRENALITIS. In doing so, we compare EFALIZUMAB with other drugs that cause ADRENALITIS, to help you evaluate whether or not EFALIZUMAB causes ADRENALITIS. Likewise, this page shows the most highly-reported side effects of EFALIZUMAB, so you can see if ADRENALITIS ranks among EFALIZUMAB's most well-known side effects.
Summary Statistics
Reports of EFALIZUMAB causing ADRENALITIS: 1
Reports of any side effect of EFALIZUMAB : 268
Percentage of EFALIZUMAB patients where ADRENALITIS is a reported side effect: 0.3731%

FDA reports of any drug causing ADRENALITIS : 27
Average percentage for all medicated patients where ADRENALITIS is reported as a complication: 0.0002%

Physician opinion on EFALIZUMAB as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing EFALIZUMAB:
PSORIASIS ( 175 patients )
GRAFT VERSUS HOST DISEASE ( 10 patients )
DRUG USE FOR UNKNOWN INDICATION ( 8 patients )
PSORIATIC ARTHROPATHY ( 4 patients )
ERYTHRODERMIC PSORIASIS ( 3 patients )
IMMUNOSUPPRESSION ( 2 patients )
SWEAT GLAND INFECTION ( 2 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 2 patients )
RENAL TRANSPLANT ( 2 patients )
PUSTULAR PSORIASIS ( 1 patients )
THROMBOCYTOPENIA ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with ADRENALITIS:

TRUVADA (7 patients)
VALGANCICLOVIR (6 patients)
DURAGESIC (6 patients)
METHOTREXATE (5 patients)
FOLIC ACID (5 patients)
ENBREL (5 patients)
BYETTA (4 patients)
COTRIM (4 patients)
FLUCONAZOLE (4 patients)
FAMOTIDINE (4 patients)
LOPINAVIR/RITONAVIR (3 patients)
URSODIOL (3 patients)
RIBAVIRIN (3 patients)
PEGASYS (3 patients)
AZITHROMYCIN (3 patients)
INCIVEK (3 patients)
DYAZIDE (2 patients)
VENOSTASIN (THIAMINE HYDROCHLORIDE, HORSE CHESTNUT EXTRACT) (2 patients)
VALGANCICLOVIR HCL (2 patients)
ADVAIR DISKUS 100/50 (2 patients)
SULFAMETHOXAZOLE AND TRIMETHOPRIM (2 patients)
DDAVP (2 patients)
FLOVENT (2 patients)
STEROIDS NOS (2 patients)
CYCLOSPORINE (2 patients)
GOLIMUMAB (2 patients)
SINGULAIR (2 patients)
BAKTAR (2 patients)
KALETRA (2 patients)
SEREVENT (2 patients)
LISINOPRIL (2 patients)
SANASTHMYL (BECLOMETASONE DIPROPIONATE) (2 patients)
LOPINAVIR AND RITONAVIR (2 patients)
ZOLOFT (2 patients)
METFORMIN HCL (2 patients)
AMITRIPTYLINE HYDROCHLORIDE (2 patients)
METOCLOPRAMIDE (2 patients)
MOVICOL (MACROGOL, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM BICARBO (2 patients)
NITROGLYCERIN (2 patients)
REGLAN (2 patients)
OXIS (FORMOTEROL) (2 patients)
PRILOSEC (2 patients)
ANTI-ASTHMATICS (2 patients)
OXYCODONE HCL (2 patients)
PANTOPRAZOLE SODIUM (2 patients)
OXYCODON KAPSELN 5MG(OXY IR CAPSULE 5 MG) (1 patients)
OXYCODON KAPSELN 5MG (OXY IR CAPSULE 5 MG)IR CAPSULE (1 patients)
RAMIPRIL (1 patients)
NORVIR (1 patients)
RETROVIR (1 patients)
AZITHROMYC (1 patients)
LOPINAVIR + RITONAVIR (LOPINAVIR + RITONAVIR) (1 patients)
SANDIMMUNE (1 patients)
LAMIVUDINE (1 patients)
IBUPROFEN (ADVIL) (1 patients)
DARUNAVIR ETHANOLATE (1 patients)
EPIVIR (1 patients)
DEPO-PROVERA (1 patients)
URSODEOXYCHOLIC ACID (1 patients)
ADRENOCORTICOTROPHIC HORMONE (1 patients)
ACETAMINOPHEN (1 patients)
EFFEXOR (1 patients)
EFALIZUMAB (1 patients)
ZIAGEN (1 patients)
ZIDOVUDINE (1 patients)
ABACAVIR (1 patients)
Most common side effects for patients taking EFALIZUMAB:
PNEUMONIA (27 patients)
PSORIASIS (22 patients)
PYREXIA (18 patients)
DRUG INEFFECTIVE (14 patients)
DEATH (13 patients)
PULMONARY EMBOLISM (11 patients)
RESPIRATORY FAILURE (11 patients)
BLADDER CANCER (10 patients)
ANAEMIA (9 patients)
ARTHRALGIA (9 patients)
VOMITING (9 patients)
LYMPHADENOPATHY (9 patients)
MALAISE (9 patients)
ANGINA PECTORIS (8 patients)
LUPUS-LIKE SYNDROME (8 patients)
PULMONARY OEDEMA (8 patients)
RASH (8 patients)
APPENDICITIS (7 patients)
DEPRESSION (7 patients)
DERMATITIS EXFOLIATIVE (7 patients)
VISUAL IMPAIRMENT (6 patients)
BREAST CANCER (6 patients)
CEREBRAL ASPERGILLOSIS (6 patients)
CHILLS (6 patients)
COMPLETED SUICIDE (6 patients)
INTRACRANIAL PRESSURE INCREASED (6 patients)
MYOCARDITIS (6 patients)
NAUSEA (6 patients)
PAPILLOEDEMA (6 patients)
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (6 patients)
CONDITION AGGRAVATED (5 patients)
ERYTHRODERMIC PSORIASIS (5 patients)
FATIGUE (5 patients)
VITAMIN B12 DEFICIENCY (5 patients)
HEADACHE (5 patients)
HYPERPYREXIA (5 patients)
WEIGHT DECREASED (5 patients)
LYMPHOCYTE MORPHOLOGY ABNORMAL (5 patients)
LYMPHOMA (5 patients)
MUSCULAR WEAKNESS (5 patients)
PSORIATIC ARTHROPATHY (5 patients)
ADRENOCORTICAL INSUFFICIENCY ACUTE (4 patients)
ARTHRITIS (4 patients)
HEPATIC ENZYME INCREASED (4 patients)
HERPES ZOSTER (4 patients)
HODGKIN'S DISEASE NODULAR SCLEROSIS STAGE IV (4 patients)
HYPERTENSION (4 patients)
SEPTIC SHOCK (4 patients)
SEPSIS (4 patients)
ABDOMINAL PAIN (3 patients)
BACK PAIN (3 patients)
BONE MARROW FAILURE (3 patients)
CARDIAC FAILURE (3 patients)
DIARRHOEA (3 patients)
ENCEPHALITIS (3 patients)
ENDOMETRIAL CANCER (3 patients)
ERYTHEMA NODOSUM (3 patients)
HEPATIC NEOPLASM MALIGNANT (3 patients)
HEPATITIS B (3 patients)
HYPERGAMMAGLOBULINAEMIA BENIGN MONOCLONAL (3 patients)
VITAMIN B1 DEFICIENCY (3 patients)
SMALL CELL LUNG CANCER STAGE UNSPECIFIED (3 patients)
PSEUDOLYMPHOMA (3 patients)
ADENOCARCINOMA (2 patients)
ALANINE AMINOTRANSFERASE INCREASED (2 patients)
AMNESIA (2 patients)
ANGIOTENSIN CONVERTING ENZYME INCREASED (2 patients)
URINARY TRACT INFECTION (2 patients)
ATRIAL FIBRILLATION (2 patients)
CARDIAC FAILURE CONGESTIVE (2 patients)
CEREBRAL HAEMORRHAGE (2 patients)
CEREBRAL INFARCTION (2 patients)
CLOSTRIDIUM DIFFICILE COLITIS (2 patients)
COAGULOPATHY (2 patients)
COMPUTERISED TOMOGRAM ABNORMAL (2 patients)
CUTANEOUS SARCOIDOSIS (2 patients)
DEEP VEIN THROMBOSIS (2 patients)
VERTIGO (2 patients)
DIVERTICULITIS (2 patients)
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (2 patients)
DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (2 patients)
DYSLIPIDAEMIA (2 patients)
ENDOCARDITIS (2 patients)
HERPES ZOSTER DISSEMINATED (2 patients)
HILAR LYMPHADENOPATHY (2 patients)
LEUKOCYTOSIS (2 patients)
SYNCOPE (2 patients)
SWEAT GLAND INFECTION (2 patients)
LUNG DISORDER (2 patients)
LUNG NEOPLASM MALIGNANT (2 patients)
LYMPHADENOPATHY MEDIASTINAL (2 patients)
MENINGITIS ASEPTIC (2 patients)
METASTASES TO LIVER (2 patients)
MULTIPLE SCLEROSIS (2 patients)
MYOCARDIAL INFARCTION (2 patients)
NEPHROLITHIASIS (2 patients)
OEDEMA (2 patients)
PENIS CARCINOMA (2 patients)
PNEUMONIA FUNGAL (2 patients)
POLYARTHRITIS (2 patients)
RHABDOMYOLYSIS (2 patients)
SARCOIDOSIS (2 patients)
SCROTAL CANCER (2 patients)
SEBORRHOEIC KERATOSIS (2 patients)
ABDOMINAL STRANGULATED HERNIA (1 patients)
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED (1 patients)
WOUND DEHISCENCE (1 patients)
ALOPECIA (1 patients)
ANGIOEDEMA (1 patients)
ANOREXIA (1 patients)
ANTIBODY TEST POSITIVE (1 patients)
APHASIA (1 patients)
APPENDICECTOMY (1 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (1 patients)
ATELECTASIS (1 patients)
AUTOIMMUNE HEPATITIS (1 patients)
B-CELL LYMPHOMA (1 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (1 patients)
BLOOD CREATININE INCREASED (1 patients)
BLOOD GLUCOSE DECREASED (1 patients)
BLOOD GLUCOSE INCREASED (1 patients)
BONE MARROW DISORDER (1 patients)
BREAST CANCER IN SITU (1 patients)
BUNDLE BRANCH BLOCK (1 patients)
CANDIDIASIS (1 patients)
CEREBELLAR INFARCTION (1 patients)
CHEST PAIN (1 patients)
CHRONIC LYMPHOCYTIC LEUKAEMIA (1 patients)
COLON CANCER (1 patients)
CONFUSIONAL STATE (1 patients)
COUGH (1 patients)
CRYPTOCOCCAL CUTANEOUS INFECTION (1 patients)
DEMYELINATION (1 patients)
DENTAL CARIES (1 patients)
DERMATITIS PSORIASIFORM (1 patients)
DIFFICULTY IN WALKING (1 patients)
DISTURBANCE IN ATTENTION (1 patients)
DIZZINESS (1 patients)
DRUG DISPENSING ERROR (1 patients)
DRUG EXPOSURE DURING PREGNANCY (1 patients)
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION (1 patients)
DRUG INTERACTION (1 patients)
DUODENAL ULCER (1 patients)
DYSPHAGIA (1 patients)
DYSPRAXIA (1 patients)
ENTEROCOCCAL INFECTION (1 patients)
EPIDEMIC NEPHROPATHY (1 patients)
EWING'S SARCOMA (1 patients)
FALL (1 patients)
FOETAL GROWTH RETARDATION (1 patients)
FOLLICULITIS (1 patients)
GUTTATE PSORIASIS (1 patients)
HAEMORRHAGE (1 patients)
HEPATITIS (1 patients)
HEPATOCELLULAR INJURY (1 patients)
HERNIA (1 patients)
HERPES VIRUS INFECTION (1 patients)
HYPERCALCAEMIA (1 patients)
HYPERKALAEMIA (1 patients)
HYPERTRIGLYCERIDAEMIA (1 patients)
HYPOAESTHESIA (1 patients)
HYPONATRAEMIA (1 patients)
HYPOTHYROIDISM (1 patients)
IMMUNE SYSTEM DISORDER (1 patients)
INJECTION SITE ERYTHEMA (1 patients)
INJECTION SITE HAEMATOMA (1 patients)
INJECTION SITE PRURITUS (1 patients)
INJECTION SITE REACTION (1 patients)
IRON DEFICIENCY ANAEMIA (1 patients)
LIPOMA (1 patients)
LOSS OF CONSCIOUSNESS (1 patients)
LUNG NEOPLASM (1 patients)
LYMPHOPROLIFERATIVE DISORDER (1 patients)
MALIGNANT FIBROUS HISTIOCYTOMA (1 patients)
MALIGNANT MELANOMA (1 patients)
MENINGITIS CRYPTOCOCCAL (1 patients)
MENINGITIS VIRAL (1 patients)
MENTAL DISORDER (1 patients)
MENTAL STATUS CHANGES (1 patients)
MOUTH ULCERATION (1 patients)
MYALGIA (1 patients)
NECK PAIN (1 patients)
NEOLOGISM (1 patients)
NEUTROPENIC SEPSIS (1 patients)
NIGHT SWEATS (1 patients)
NODULE (1 patients)
NUCLEAR MAGNETIC RESONANCE IMAGING BRAIN ABNORMAL (1 patients)
OPTIC NEURITIS (1 patients)
OPTIC NEUROPATHY (1 patients)
OVARIAN ENLARGEMENT (1 patients)
PANCYTOPENIA (1 patients)
PAPILLOMA VIRAL INFECTION (1 patients)
PARAESTHESIA (1 patients)
PARKINSON'S DISEASE (1 patients)
PERIPHERAL SENSORY NEUROPATHY (1 patients)
PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED (1 patients)
PERITONITIS (1 patients)
PHARYNGOLARYNGEAL PAIN (1 patients)
PHONOPHOBIA (1 patients)
PHOTOPHOBIA (1 patients)
PHOTOSENSITIVITY REACTION (1 patients)
PITYRIASIS RUBRA PILARIS (1 patients)
PLEURAL EFFUSION (1 patients)
PNEUMONITIS (1 patients)
PRURITUS (1 patients)
RASH GENERALISED (1 patients)
RASH MACULAR (1 patients)
RASH PAPULAR (1 patients)
REBOUND EFFECT (1 patients)
RENAL FAILURE ACUTE (1 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent FactMed Activity for EFALIZUMAB


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ADRENALITIS and EFALIZUMAB, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking EFALIZUMAB, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in EFALIZUMAB. This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for EFALIZUMAB experts. If you are a healthcare provider experienced in prescribing EFALIZUMAB, please register here.

Your online appointment book for New Brunswick Rentals & Services

Chef and Catering services in New Brunswick
Chiropracter and Massage services in New Brunswick
Event and Wedding Planning services in New Brunswick
Hair Styling services in New Brunswick
Personal Shopping services in New Brunswick
Photography and Videography services in New Brunswick
Private Investigation services in New Brunswick
Website Design services in New Brunswick

Home
Appliance Repair services in New Brunswick
Appraisals services in New Brunswick
Awnings services in New Brunswick
Builder Services services in New Brunswick
Carpentry services in New Brunswick
Cleaning services in New Brunswick
Decks and Porches services in New Brunswick
Electricians services in New Brunswick
Fireplace services in New Brunswick
Generators services in New Brunswick
Greenhouses and Nurseries services in New Brunswick
Handymen services in New Brunswick
Home Security services in New Brunswick
HVAC services in New Brunswick
Insulation services in New Brunswick
Interior Design services in New Brunswick
Landscaping services in New Brunswick
Lawn and Yard services in New Brunswick
Locksmiths services in New Brunswick
Marble and Granite Experts services in New Brunswick
Masonry services in New Brunswick
Moving Services services in New Brunswick
Painters services in New Brunswick
Plumbing services in New Brunswick
Pool and Spa services in New Brunswick
Property Management services in New Brunswick
Roofers services in New Brunswick
Snow Plowing services in New Brunswick
Solar Power Consultants services in New Brunswick
Upholstery services in New Brunswick
Wallpaper services in New Brunswick
Waterproofing services in New Brunswick
Windows services in New Brunswick
Services - Other



© 2014 FactMed, Inc
Privacy Policy
Terms of Use